AsclepiX Therapeutics closed $35 million in Series A financing to fund its upcoming clinical trials of AXT107 to treat various retinal diseases, according to a press release.
The funding was led by the Perceptive Xontogeny Venture Fund and joined by the Perceptive Life Sciences Fund, both managed by Perceptive Advisors. Existing investors included Rapha Capital Management and Barer & Son Capital.
The funds will finance phase 1/2a clinical trials of AXT107, the company’s lead investigational drug, for the treatment of diabetic macular edema, wet age-related macular degeneration and
Uncategorized